Announced details
Dermatology and the exploration of drug discovery target candidates for inflammatory diseases
DDAIF has been adopted by multiple major pharmaceutical companies and has built up a track record (the names and number of adopting companies are Not disclosed). The first project identified multiple drug discovery target candidates.
FRONTEO and マルホ are conducting a co-creation project to explore drug discovery targets in dermatology. This is the second project, following the first; capital and personnel relationships are Not disclosed.
A pharmaceutical company headquartered in Kita Ward, Osaka City, engaged in the research, development, manufacture and sale of prescription pharmaceuticals and other products. Founded in 1915, it had 1,632 employees as of the end of September 2025 and sales of ¥78.924 billion for the fiscal year ended September 2025. The representative director and president is Sugita Jun (杉田 淳).
KIBIT-related technologies have obtained 21 patents in total in Japan, Europe, the United States and South Korea. Expiration dates and individual patent numbers are Not disclosed.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Drug Discovery AI Factory（DDAIF）, KIBIT |
| Counterparty | Maruho Co., Ltd. |
| Counterparty overview | A pharmaceutical company headquartered in Kita Ward, Osaka City, engaged in the research, development, manufacture and sale of prescription pharmaceuticals and other products. Founded in 1915, it had 1,632 employees as of the end of September 2025 and sales of ¥78.924 billion for the fiscal year ended September 2025. The representative director and president is Sugita Jun (杉田 淳). |
| Relationship with the Company | FRONTEO and マルホ are conducting a co-creation project to explore drug discovery targets in dermatology. This is the second project, following the first; capital and personnel relationships are Not disclosed. |
| Launch date | 29 October 2026 (actual start of the second co-creation project) |
| Applicable area | Dermatology and the exploration of drug discovery target candidates for inflammatory diseases |
| Registration number and expiry date | KIBIT-related technologies have obtained 21 patents in total in Japan, Europe, the United States and South Korea. Expiration dates and individual patent numbers are Not disclosed. |
| Usage history | DDAIF has been adopted by multiple major pharmaceutical companies and has built up a track record (the names and number of adopting companies are Not disclosed). The first project identified multiple drug discovery target candidates. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The project combines マルホ's expertise in dermatology and drug discovery research with FRONTEO's AI analysis technology and the research and hypothesis-building capabilities of its drug discovery researchers, with the aim of creating innovative pharmaceuticals and addressing unmet medical needs.